# MURANO (NCT02005471)

> A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02005471
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Chronic Lymphocytic Leukemia
- Interventions: Bendamustine; Venetoclax; Rituximab
- Enrollment: 389
- Primary outcome: Percentage of Participants With PD as Assessed by the Investigator Using Standard International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Guidelines or Death
- Primary outcome: Progression-Free Survival (PFS) as Assessed by the Investigator Using Standard iwCLL Guidelines

## Commentary we found

- YouTube: 70
- Podcasts: 51
- X threads: 13
- X videos: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=murano-nct02005471

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02005471", "email": "<work email>"}; the inbox owner confirms by the emailed link.